Alpha 2.0
Login Register
» Authors » A Kuijer

A Kuijer

Explore the profile of A Kuijer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 39
Followers 0
Related Specialties
Oncology
Genetics
Top 10 Co-Authors
S G Elias
T van Dalen
C H Smorenburg
S Siesling
Th van Dalen
E J Th Rutgers
A Jager
C A Drukker
C H van Gils
J Verloop
Published In
Eur J Cancer
Genet Med
Ann Oncol
Int J Cancer
Breast Cancer Res Treat
Affiliations
Soon will be listed here.
Recent Articles
1.
The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer
van Steenhoven J, Kuijer A, Schreuder K, Elias S, van Diest P, van der Wall E, et al.
Ann Surg Oncol . 2019 Jun; 26(11):3495-3501. PMID: 31209664
Purpose: We assessed the recent trends in the administration of adjuvant chemotherapy thereby evaluating the role of the 70-gene signature (70-GS) testing in decision-making in the systemic treatment of patients...
2.
Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area
Schreuder K, Kuijer A, Rutgers E, Smorenburg C, van Dalen T, Siesling S
Eur J Cancer . 2017 Aug; 84:270-277. PMID: 28844015
Purpose: In Dutch guidelines, gene expression profiles (GEP) are indicated in estrogen receptor positive early breast cancer patients in whom benefit of chemotherapy (CT) is uncertain based on traditional prognostic...
3.
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial
Aalders K, Kuijer A, Straver M, Slaets L, Litiere S, Viale G, et al.
Eur J Cancer . 2017 May; 79:98-105. PMID: 28477490
Background: In multifocal breast cancer, guidelines recommend basing adjuvant systemic treatment decisions on characteristics of the largest lesion, disregarding multifocality as an independent prognosticator. We assessed the association between multifocal...
4.
The influence of socioeconomic status and ethnicity on adjuvant systemic treatment guideline adherence for early-stage breast cancer in the Netherlands
Kuijer A, Verloop J, Visser O, Sonke G, Jager A, van Gils C, et al.
Ann Oncol . 2017 May; 28(8):1970-1978. PMID: 28459994
Background: We aimed to assess whether socioeconomic status (SES) and ethnicity affect adjuvant systemic therapy (AST) guideline adherence in early breast cancer patients in a health care setting with assumed...
5.
Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level
Verschoor A, Kuijer A, Verloop J, van Gils C, Sonke G, Jager A, et al.
Breast Cancer Res Treat . 2016 Aug; 159(2):357-65. PMID: 27514397
Over recent years, adjuvant systemic treatment guidelines (AST) for early-stage breast cancer have changed considerably. We aimed to assess the impact of these guideline changes on the administration of AST...
6.
Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study
Kuijer A, Drukker C, Elias S, Smorenburg C, Rutgers E, Siesling S, et al.
Int J Cancer . 2016 Apr; 139(4):769-75. PMID: 27062369
Ten years ago gene-expression profiles were introduced to aid adjuvant chemotherapy decision making in breast cancer. Since then subsequent national guidelines gradually expanded the indication area for adjuvant chemotherapy. In...
7.
Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study
Kuijer A, van Bommel A, Drukker C, van der Heiden-van der Loo M, Smorenburg C, Westenend P, et al.
Genet Med . 2015 Nov; 18(7):720-6. PMID: 26583684
Purpose: The Dutch national guideline advises use of gene-expression signatures, such as the 70-gene signature (70-GS), in case of ambivalence regarding the benefit of adjuvant chemotherapy (CT). In this nationwide...